Graham Capital Management’s Gilead Sciences GILD Stock Holding History

Graham Capital Management’s Portfolio GILD Stock Details GILD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-18,886	Closed	-$1.74M	–	1366
2024 Q4	$1.74M	Buy	+18,886	New	+$1.7M	0.03%	331
2022 Q3	–	Sell	-17,904	Closed	-$1.11M	–	1148
2022 Q2	$1.11M	Buy	+17,904	New	+$1.11M	0.04%	405
2022 Q1	–	Sell	-2,896	Closed	-$210K	–	935
2021 Q4	$210K	Buy	+2,896	New	+$199K	0.01%	450
2017 Q3	–	Sell	-16,600	Closed	-$1.18M	–	71
2017 Q2	$1.18M	Buy	+16,600	New	+$1.1M	0.03%	53
2015 Q2	–	Sell	-69,792	Closed	-$6.85M	–	127
2015 Q1	$6.85M	Buy	69,792 +28,050	+67%	+$2.85M	0.34%	64
2014 Q4	$3.94M	Buy	+41,742	New	+$4.32M	0.17%	80
2014 Q2	–	Sell	-10,300	Closed	-$802K	–	162
2014 Q1	$730K	Buy	+10,300	New	+$808K	0.04%	93

Other funds holding GILD

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Graham Capital Management's GILD Position: Q1 2025 in Review

Graham Capital Management sold out of Gilead Sciences (GILD) in Q1 2025, closing a stake of 18,886 shares — an estimated $1.74M sold.

Graham Capital Management first reported a position in GILD in Q1 2014 and held it in 7 quarters. The position peaked at $6.85M in Q1 2015. 2,013 funds tracked by Wall St. Rank hold GILD as of Q1 2025.

Graham Capital Management reported no remaining Gilead Sciences position as of Q1 2025 after selling out during the quarter.
Graham Capital Management sold 18,886 Gilead Sciences shares in Q1 2025, an estimated $1.74M.
Graham Capital Management first reported a position in Gilead Sciences in Q1 2014 and held it in 7 quarters.
Graham Capital Management's Gilead Sciences position peaked at $6.85M in Q1 2015.
2,013 funds tracked by Wall St. Rank held Gilead Sciences as of Q1 2025.

Based on Graham Capital Management's 13F filing for Q1 2025, filed 15 May 2025.